• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Savara prices $113M offering

March 11, 2021 By Sean Whooley

SavaraSavara (NSDQ:SVRA) announced today that it priced an underwritten public offering of common stock at approximately $113 million.

Austin, Texas-based Savara — an orphan lung disease treatment company with an inhaled formulation of recombinant human GM-CSF — is offering nearly 45.8 million shares of its common stock to the public for $1.45 per share, according to a news release.

In addition to those shares, Savara offered to certain existing investors pre-funded warrants to purchase nearly 32.2 million shares of common stock at $1.449 per warrant in place of shares of common stock that are available to the public.

On top of the initial common stock and warrants to purchase common stock on offer, Savara granted underwriters a 30-day option to purchase up to 11.7 million additional shares at the public offering price.

Savara expects the offering to close on March 15. It’ll use the money to support operations. The company’s work includes clinical development, manufacturing, regulatory and commercial activities related to its molgramostim nebulizer solution (molgramostim, formerly referred to as Molgradex) for treating autoimmune pulmonary alveolar proteinosis (aPAP) — and the IMPALA 2 trial.

Jefferies and Piper Sandler are acting as joint book-running managers and representatives of the underwriters for the offering. Oppenheimer & Co. is acting as the lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup Tagged With: Savara Inc.

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS